How long does Wegovy 1.7mg stay in your system?

Step 1, understand what the half-life actually tells you

Half-life is the time it takes for the concentration of a drug in your body to fall by half. The NHS semaglutide medicines page confirms that semaglutide has an elimination half-life of around seven days, which is unusually long for an injectable medicine. The practical consequence: one missed 1.7mg dose does not clear your system overnight. After one week without an injection, roughly half the drug is still circulating. After two weeks, about a quarter remains. Full clearance takes five weeks, not five days.

That long half-life is part of the design. Weekly dosing is possible precisely because the drug persists at therapeutic concentrations between injections. It also means the medicine keeps working for several weeks after you stop, then fades gradually rather than dropping off a cliff. Some people find nausea improves in the days after a missed dose for exactly this reason.

If you want a sense of how long 1mg Wegovy stays in your system, that page explains the clearance timeline at that earlier titration stage, which differs meaningfully from the picture at 1.7mg. If you also want to compare with the top of the titration schedule, the 2.4mg clearance page covers the maintenance-dose timeline.

Step 2, know where 1.7mg sits in the titration sequence

The 1.7mg dose is not a maintenance dose. It is the penultimate step in the standard Wegovy titration schedule: 0.25mg, 0.5mg, 1.0mg, 1.7mg, 2.4mg, each held for roughly four weeks at the prescriber's discretion. The full Wegovy dosage progression page walks through the rationale behind each step.

Reaching steady state (the point where the amount of drug entering your body each week matches the amount leaving) takes four to five weeks at 1.7mg. That timing is why prescribers generally do not assess how you are tolerating a dose until you have been on it for a full month. Evaluating appetite suppression or side effects in week one of a new dose is evaluating a moving target.

One practical check worth doing: look at the date on your last 1.7mg pen. If your next scheduled dose is more than ten days away, contact your prescriber before injecting, the standard guidance is that a dose delayed by more than ten days should be discussed rather than simply taken late. Your Patient Information Leaflet has the exact wording; your prescriber has the context.

Step 3, plan around clearance for surgery, conception or stopping

The five-week window is clinically relevant in three common situations. First, surgery: NHS England advises patients to tell their anaesthetist they are taking a GLP-1 medicine. Slowed gastric emptying, a known effect of semaglutide, raises aspiration risk under general anaesthesia, and the drug's long half-life means it is still active well after you feel 'normal'. Do not self-manage this; your surgical team needs the information.

Second, conception: the MHRA advises against using semaglutide if you are pregnant, breastfeeding, or actively trying to conceive. Clearance guidance specific to this situation (including timing before trying to conceive) comes from your prescriber, not an estimated five-week figure read online. The semaglutide clearance after stopping page has more detail on what happens post-final-dose.

Third, simply stopping mid-titration: some people pause at 1.7mg for tolerability reasons or personal choice. Weight regain after stopping GLP-1 medicines is well documented in clinical literature. That is not a reason to continue if stopping is right for you medically, but it is a reason to have the conversation with a prescriber rather than quietly skipping your next pen. For a broader look at the treatment and what it involves, the Wegovy overview covers the licensed uses, eligibility and evidence.

How cost and continuity decisions interact with the clearance window

A pattern worth naming: some people consider pausing or stopping Wegovy for financial reasons partway through titration. The clearance timeline is relevant here too. If you pause at 1.7mg and restart several weeks later, you are essentially restarting with very low circulating drug, and your prescriber may recommend stepping back down the titration schedule rather than resuming at 1.7mg, to avoid a spike in side effects. That restart process affects both your experience and the overall cost of treatment. The Wegovy cost comparison page breaks down what legitimate private pricing actually includes, which is worth reading before pausing on cost grounds alone.

Wegovy is a prescription-only medicine. Any decision about stopping, pausing, or adjusting your dose belongs with your prescriber. If you have not yet started and are weighing your options, you can speak to our prescribers through a free consultation, reviewed the same day by a real clinician, not software.